SUO 2020: Next Generation Clinical Trial Design BCG-Unresponsive NMIBC
SUO 2020: Next Generation Clinical Trial Design BCG-Unresponsive NMIBC (UroToday.com) There have been several recent single-arm trials in the Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) setting (Table 1). The first question that arises is whether these single-arm trials are enough or do we need to randomize patients for our future trials. As seen in Table 1, these treatments are given for a minimum of two years, requiring a high number of physician visits during these treatment years. To get more accurate information, we may need to consider rando...
Source: urotoday.com